Jurata Thin Film, Inc.

Based in Texas, US, and founded in 2019 by CEO Sheila Ann Mikhail and Maria Croyle, Jurata Thin Film operates as a company specializing in vaccine and biologic manufacturing, distribution, and storage for medical and healthcare clients. In November 2022, Jurata Thin Film raised USD 4. 87 million in seed funding led by Golden Seeds, with participation from Columbus Venture Capital, Ferocity Capital, and The University of Texas at Austin, along with the company's management, who also participated in the round.   Jurata Thin Film provides technology to stabilize biological materials in a thermostable film matrix, which removes cold chain logistics in pharmaceutical fill/finish, distribution, storage, and delivery.

The company supports the delivery of vaccines and therapeutic payloads through buccal and sublingual routes. In addition, the firm provides clients with storage at room temperature for vaccines and other life-saving medications.   The company plans to use November 2022 funds for designing and building a pilot-scale manufacturing line capable of fabricating over 1,000 doses of vaccine- or biologic-loaded thin films per hour and to support the requisite toxicity studies demonstrating the safety of its formulation for administration under the tongue (sublingual), inside the cheek (buccal), or through intramuscular injection after rehydration.